Clinical trialNCT03947255TerminatedPhase 2Interventional

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

SponsorSeagen Inc.Enrollment12Anaplastic Large Cell LymphomaHodgkin LymphomaPeripheral T Cell Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stopping treatment.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Dominic Lai, MD
Seagen Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Pacific Cancer Medical Center
Anaheim, California, United States
Scl Health Good Samaritan Medical Center Cancer Centers of Colorado
Lafayette, Colorado, United States
Memorial Cancer Institute
Pembroke Pines, Florida, United States
Northwest Oncology and Hematology/amita
Elk Grove Village, Illinois, United States
Cardinal Bernardin Cancer Center / Loyola University Medical Center
Maywood, Illinois, United States
Norton Cancer Institute
Louisville, Kentucky, United States
Tulane University Hospital and Clinic
New Orleans, Louisiana, United States
University of Maryland
Baltimore, Maryland, United States
Karmanos Cancer Institute / Wayne State University
Detroit, Michigan, United States
Saint Louis University
St Louis, Missouri, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Summit Medical Group
Florham Park, New Jersey, United States
Medical University of South Carolina/hollings Cancer Center
Charleston, South Carolina, United States
Texas Oncology - Fort Worth
Dallas, Texas, United States
Texas Oncology - Fort Worth 12th Avenue
Fort Worth, Texas, United States
the Center for Cancer and Blood Disorders: Fortworth
Fort Worth, Texas, United States
Houston Methodist Cancer Center
Houston, Texas, United States
Md Anderson Cancer Center / University of Texas
Houston, Texas, United States
Texas Oncology - San Antonio Medical Center
San Antonio, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Brentuximab vedotin

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Oct 2019
Primary completion: 6 Nov 2022
Completion: 6 Nov 2022
Last update posted: 13 Oct 2023
Registered enrollment: 12
Registry id: NCT03947255

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.